AbbVie Inc. $ABBV Stock: Sepio Capital LP Boosts Position

Key Points

• Sepio Capital LP increased its AbbVie stake by 475.7% in the third quarter, acquiring 619,274 additional shares and making AbbVie its second-largest holding at 7.9% of its portfolio. Institutional investors and hedge funds collectively own 70.23% of ABBV.
• AbbVie reported quarterly revenue of $16.99 billion and earnings of $3.65 per share, exceeding analyst expectations, while revenue grew 10.2% year over year. The stock traded near its 52-week high, with a market capitalization of approximately $504.7 billion.
• The company declared a quarterly dividend of $1.73, equivalent to an annualized $6.92 payout and a 2.4% yield. Analysts maintained a generally positive outlook, giving AbbVie a consensus “Moderate Buy” rating and an average price target of $279.86.

Sepio Capital LP grew its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 475.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 749,451 shares of the company's stock after acquiring an additional 619,274 shares during the period. AbbVie comprises 7.9% of Sepio Capital LP's investment portfolio, making the stock its 2nd biggest holding. Sepio Capital LP's holdings in AbbVie were worth $196,049,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in ABBV. State Street Corp grew its holdings in shares of AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company's stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of AbbVie by 0.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock worth $3,590,323,000 after buying an additional 106,091 shares in the last quarter. Legal & General Group Plc acquired a new stake in AbbVie in the second quarter valued at approximately $2,905,952,000. Deutsche Bank AG grew its holdings in AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after acquiring an additional 1,241,587 shares in the last quarter. Finally, Amundi raised its holdings in shares of AbbVie by 2.4% in the 1st quarter. Amundi now owns 10,698,095 shares of the company's stock valued at $2,326,728,000 after purchasing an additional 247,689 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

NYSE ABBV traded up $0.47 during trading hours on Friday, reaching $285.66. The company's stock had a trading volume of 4,625,678 shares, compared to its average volume of 5,199,403. The company's 50-day moving average is $266.33 and its two-hundred day moving average is $241.77. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $291.40. The stock has a market cap of $504.70 billion, a PE ratio of 80.69, a PEG ratio of 1.30 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period last year, the company posted $2.97 EPS. The company's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts expect that AbbVie Inc. will post 13.93 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie's payout ratio is 195.48%.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABBV. BMO Capital Markets upped their price objective on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Royal Bank Of Canada reiterated an "outperform" rating and set a $280.00 target price on shares of AbbVie in a research report on Tuesday, October 13th. Leerink Partners lifted their price target on AbbVie from $245.00 to $279.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 5th. Bank of America reiterated a "buy" rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, Scotiabank raised their price target on AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $279.86.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. FDA approved a subcutaneous induction regimen for SKYRIZI in adults with moderately to severely active Crohn’s disease. The on-body injector provides a more convenient administration option throughout treatment, while Phase 3 data showed superior clinical remission and endoscopic response versus placebo with no new safety risks. The approval could strengthen SKYRIZI’s commercial position and support AbbVie’s post-Humira growth strategy. FDA approves subcutaneous SKYRIZI induction for Crohn’s disease
• Positive Sentiment: AbbVie’s dividend remains a key defensive attraction. Analysts and financial commentators point to the company’s ability to maintain shareholder payouts despite Humira’s patent loss, supported by growth from SKYRIZI, RINVOQ and other newer products. AbbVie’s dividend after Humira’s patent cliff
• Neutral Sentiment: AbbVie’s Phase 3 INTREPID trial for lutikizumab in hidradenitis suppurativa met its primary endpoint and eight ranked secondary endpoints, including reduced pain and fewer flares. However, reported efficacy was viewed by some analysts as underwhelming relative to competing treatments, leaving the drug’s eventual commercial opportunity uncertain. AbbVie reports Phase 3 INTREPID results for lutikizumab
• Negative Sentiment: Investors are approaching next week’s earnings report cautiously. Erste Group lowered its 2026 EPS estimate to $13.90 from $14.00, slightly below the roughly $13.94 consensus, while a Zacks preview said AbbVie lacks the usual indicators for a likely earnings beat. With the shares trading near their 52-week high and at a premium valuation, results and guidance may need to be strong to sustain momentum. AbbVie earnings preview

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.